NICE maintains position not to recommend SCENESSE
Filed with ASX · · 2 pages · English
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL Regulatory Update
- CLINUVEL to take 100% ownership of VALLAURIX joint venture
- CLINUVEL hosts European EPP Expert Meeting
- Preliminary assessment received from NICE
- CLINUVEL provides update on SCENESSE FDA filing
Later from Clinuvel Pharmaceuticals
- CLINUVEL completes SCENESSE FDA Filing
- US FDA Update
- S&P DJI Announces September 2018 Quarterly Rebalance
- Appeal Upheld Against NICE Recommendation in England
- CUV103 Singaporean Phase II vitiligo study results
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals